Price History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Trend
Price above all key MAs — strong uptrend
Price Action
Support & Resistance Levels
Volume Analysis
Stop Loss Levels
Fixed Risk
Technical Levels
Moving Averages
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹172.7 Cr | ₹137.2 Cr | ₹168.9 Cr | ₹180 Cr |
| Net Profit | ₹34.9 Cr | ₹117.4 Cr | ₹26.3 Cr | ₹22.1 Cr |
| EPS | ₹21.12 | — | ₹15.90 | ₹13.38 |
| Operating Profit | ₹52.5 Cr | ₹140.5 Cr | ₹40.7 Cr | ₹34.8 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 27 Jun 2025 | Dividend - Rs 20 Per Share/ Special Dividend - Rs 4 Per Share | SPECIAL_DIVIDEND |
| 28 Jun 2024 | Dividend - Rs 16 Per Share | DIVIDEND |
| 21 Jul 2023 | Dividend - Rs 12 Per Share | DIVIDEND |
| 14 Jul 2022 | Dividend - Rs 9.60 Per Share | DIVIDEND |
| 13 Aug 2021 | Dividend - Rs 7.20 Per Share | DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for RPGLIFE
View All
Anupam Rasayan becomes world's first to make ETFA using flow chemistry
Anupam Rasayan India Ltd has achieved a global first by commercialising Ethyl trifluoroacetate production using its unique continuous flow chemistry technology. This advanced method offers enhanced safety and efficiency over traditional batch processes. ETFA is a vital component for pharmaceuticals and life sciences.
Multibagger Anupam Rasayan stock to be in focus on Friday on ETFA manufacturing milestone
Anupam Rasayan India announces commercialization of ETFA production via a proprietary continuous flow chemistry platform, making it the first globally to do so. The market potential for ETFA is $500-600 million, crucial for fluorinated compounds in pharmaceuticals and life sciences.
Analysts project up to 17% upside in healthcare stocks trading at new highs
Apollo Hospitals, Aster DM Healthcare, Sai Life Sciences have rallied up to 27% thus far in FY27; technical analysts remain bullish on these stocks given the favourable chart set-up.